0001104659-21-082064.txt : 20210616 0001104659-21-082064.hdr.sgml : 20210616 20210616170607 ACCESSION NUMBER: 0001104659-21-082064 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210614 FILED AS OF DATE: 20210616 DATE AS OF CHANGE: 20210616 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vogt Frederick G CENTRAL INDEX KEY: 0001719678 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36860 FILM NUMBER: 211022236 MAIL ADDRESS: STREET 1: 2120 HEMLOCK RD. CITY: WEST NORRITON STATE: PA ZIP: 19403 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IOVANCE BIOTHERAPEUTICS, INC. CENTRAL INDEX KEY: 0001425205 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 753254381 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 999 SKYWAY ROAD STREET 2: SUITE 150 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 6502607120 MAIL ADDRESS: STREET 1: 999 SKYWAY ROAD STREET 2: SUITE 150 CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: Lion Biotechnologies, Inc. DATE OF NAME CHANGE: 20131015 FORMER COMPANY: FORMER CONFORMED NAME: Genesis Biopharma, Inc DATE OF NAME CHANGE: 20100319 FORMER COMPANY: FORMER CONFORMED NAME: FREIGHT MANAGEMENT CORP DATE OF NAME CHANGE: 20080128 4 1 tm2119923-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-06-14 0 0001425205 IOVANCE BIOTHERAPEUTICS, INC. IOVA 0001719678 Vogt Frederick G C/O IOVANCE BIOTHERAPEUTICS, INC. 999 SKYWAY ROAD, SUITE 150 SAN CARLOS CA 94070 0 1 0 0 Interim CEO & General Counsel Stock Option (right to buy) 23.87 2021-06-14 4 A 0 100000 0 A 2031-06-14 Common Stock 100000 100000 D Stock Option (right to buy) 23.87 2021-06-14 4 A 0 73900 0 A 2031-06-14 Common Stock 73900 73900 D Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-half of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest on December 31, 2022. /s/ Frederick G. Vogt 2021-06-16